XML 45 R33.htm IDEA: XBRL DOCUMENT v3.25.1

Stockholders’ Deficiency (Tables)

3 Months Ended

Mar. 31, 2025

Stockholders’ Deficiency [Abstract]

Schedule of Activity for the Warrants

The schedule of activity for the warrants is as follows:

		Number of Warrants				Weighted Average Exercise Price (as converted)				Remaining Contractual Term (Years)
Balance, December 31, 2024			3,635,962			$	7.37				3.30
Balance, March 31, 2025			3,635,962			$	7.37				3.05

Schedule of Warrants Outstanding and Exercisable

A summary of the warrants outstanding and exercisable as of March 31, 2025, is as follows:

Warrants Outstanding				Exercise Price				Expiry Date
	133,193			$	7.75			August 31, 2026
	35,064			$	7.75			October 16, 2026
	101,000			$	7.75			November 8, 2026
	394,572			$	7.75			December 22, 2026
	720,123			$	7.75			January 19, 2027
	585,609			$	7.23			February 16, 2028
	86,200			$	6.78 (CAD$9.75	)		February 16, 2028
	28,796			$	6.78 (CAD$9.75	)		March 15, 2028
	262,287			$	7.08			March 15, 2028
	430,805			$	7.19			September 24, 2029
	642,892			$	7.18			November 8, 2029
	215,421			$	7.19			November 13, 2029
	3,635,962

A summary of warrants not issued for services with CAD exercise prices outstanding and exercisable as of March 31, 2025, is as follows:

Warrants Outstanding				Exercise Price				Expiry Date
	86,200			$	6.78 (CAD$9.75	)		February 16, 2028
	15,810			$	6.78 (CAD$9.75	)		March 15, 2028
	102,010

A summary of the Initial and Additional Debenture Warrants issued and outstanding as of March 31, 2025, is as follows:

Warrants Outstanding				Exercise Price				Expiry Date
	430,805			$	7.19			September 24, 2029
	215,421			$	7.19			November 13, 2029
	646,226

A summary of the agent warrants issued and outstanding as of March 31, 2025, is as follows:

Warrants Outstanding				Exercise Price				Expiry Date
	642,892			$	7.18			November 9, 2029

Schedule of Derivative Liability

As of March 31, 2025 and December 31, 2024, the Company revalued the derivative liability to $415,434 and $503,129, respectively, and recorded a gain on revaluation of $87,695 for the three months ended March 31, 2025 (three months ended March 31, 2024 – loss of $619,989).

Balance as of December 31, 2024		$	503,129
Revaluation of derivative liability			(87,695	)
Balance as of March 31, 2025		$	415,434

Schedule of Weighted Average Assumptions were used in the Black-Scholes Option-Pricing Model

The following weighted average assumptions were used in the Black-Scholes option-pricing model for the re-valuations as of March 31, 2025 and December 31, 2024: 

		March 31, 2025				December 31, 2024
Risk-free interest rate			4.27	%			4.27	%
Dividend yield			-				-
Expected life (in years)			2.89				3.14
Volatility			158	%			158	%
Weighted average fair value per warrant		$	4.07			$	4.93

The following weighted average assumptions were used in the Black-Scholes option-pricing model for the revaluation for the Initial and Additional Debenture Warrant as of December 31, 2024 and March 31, 2025:

		March 31, 2025				December 31, 2024
Risk-free interest rate			3.96	%			4.38	%
Dividend yield			-				-
Expected life (in years)			4.53				4.73
Volatility			93	%			94	%

The following weighted average assumptions were used in the Black-Scholes option-pricing model for the revaluations:

		March 31, 2025				December 31, 2024
Risk-free interest rate			3.96	%			4.38	%
Dividend yield			-				-
Expected life (in years)			4.61				4.86
Volatility			94	%			95	%

The following weighted average assumptions were used in the Black-Scholes option-pricing model for the valuation of the Common Share options issued:

		March 31, 2025				December 31, 2024
Risk-free interest rate			4.31	%			4.34	%
Expected life (in years)			10				10
Volatility			82	%			82	%
Weighted average fair value per option		$	4.91			$	5.58

Schedule of Share-Based Compensation Expense

The following table summarizes the total amount of share-based compensation expense related to service conditions for Common Share options during the three months ended March 31, 2025, and 2024:

		For the Three Months Ended
		March 31, 2025				March 31, 2024
Research and development		$	33,079			$	87,847
General and administrative			1,322,294				260,238
Total share-based compensation		$	1,355,373			$	348,085

Schedule of Common Share Option Activity

Common share option activity is as follows:

		Number of Options				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life (Years)				Aggregate Intrinsic Value(1)
Balance, December 31, 2024			888,529			$	4.58				8.36			$	1,159,843
Granted			1,165,522				5.93
Balance, March 31, 2025			2,054,121				5.32				8.80				725,617
Options exercisable, March 31, 2025			746,240			$	4.50				7.20			$	563,504

(1) The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company’s common share. The calculation excludes options with an exercise price higher than the closing price of the Company’s share on the reporting date.

The following table summarizes ACI Canada legacy performance option activity for the Company:

		Number of Options				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life (Years)				Aggregate Intrinsic Value(1)
Balance, December 31, 2024			265,642				0.22				3.48				1,506,321
Balance, March 31, 2025			265,642				0.22				3.23				1,285,838
Options exercisable, March 31, 2025			258,362			$	0.22				3.21			$	1,250,821

(1) The aggregate intrinsic values were calculated as the difference between the exercise price of the options and the closing price of the Company’s common share. The calculation excludes options with an exercise price higher than the closing price of the Company’s shares on the reporting date

Schedule of Common Share Options Outstanding

A summary of the Common Share options outstanding at March 31, 2025, is as follows:

Options Outstanding				Options Exercisable				Exercise Price					Expiry Date
	7,300				7,300				4.87	(CAD$7.00	)		September 30, 2025
	82,367				82,367				3.83	(CAD$5.50	)		September 30, 2025
	1,566				1,566			$	10.00				June 1, 2029
	1,566				1,566			$	10.00				July 22, 2030
	104,000				104,000			$	4.87	(CAD$7.00	)		August 3, 2031
	37,600				37,600			$	4.87	(CAD$7.00	)		December 20, 2031
	8,600				8,600			$	4.87	(CAD$7.00	)		February 14, 2032
	18,000				18,000			$	4.87	(CAD$7.00	)		May 31, 2032
	477,600				347,006			$	3.83	(CAD$5.50	)		June 8, 2033
	32,000				2,667			$	10.43	(CAD$15.00	)		October 21, 2034
	84,000				7,001			$	5.70	(CAD$8.20	)		November 26, 2034
	34,000				2,834			$	5.03				December 24, 2034
	10,000				-				6.00				January 14, 2035
	52,500				-				5.80				February 12, 2035
	1,005,822				125,732				5.93				February 25, 2035
	8,000				-				5.75				March 4, 2035
	89,200				-				5.55				March 20, 2035
	2,054,121				746,240

Schedule of Canada Legacy Performance Options Outstanding

A summary of the ACI Canada legacy performance options outstanding at March 31, 2025, is as follows:

Options Outstanding				Options Exercisable				Exercise Price				Expiry Date
	36,000				36,000			$	0.025			February 1, 2026
	27,642				27,642			$	0.25			December 31, 2027
	122,000				121,120			$	0.25			September 1, 2028
	80,000				73,600			$	0.25			June 1, 2029
	265,642				258,362

X

- Definition

Tabular disclosure of activity for the warrants.

+ References

No definition available.

+ Details

Name:	acog_ScheduleOfActivityForTheWarrantsTableTextBlock
Namespace Prefix:	acog_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of Canada Legacy Performance Options Outstanding.

+ References

No definition available.

+ Details

Name:	acog_ScheduleOfCanadaLegacyPerformanceOptionsOutstandingTableTextBlock
Namespace Prefix:	acog_
Data Type:	dtr:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_EquityAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of derivative liabilities at fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B

+ Details

Name:	us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (f)(2)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration